The National Drug Alliance Procurement Office in China has published the winning results of the continued tender for insulin volume-based procurement (VBP), with 14 insulin products securing the available slots. Notably, protamine recombinant human insulin mixed injection (30/70) and insulin detemir, which were part of the previous round, did not make the cut this time.
The final results align with the preliminary winning results, and the new procurement terms are set to take effect from the next month, reflecting the ongoing efforts to streamline access to insulin for the Chinese population.- Flcube.com
